Cancer Treatment Patterns and Factors Affecting Receipt of Treatment in Older Adults: Results from the ASPREE Cancer Treatment Substudy (ACTS)

Abstract

Introduction: Cancer treatment planning in older adults is complex and requires careful balancing of survival, quality of life benefits, and risk of treatment-related morbidity and toxicity. As a result, treatment selection in this cohort tends to differ from that for younger patients. However, there are very few studies describing cancer treatment patterns in older cohorts. Methods: We used data from the ASPirin in Reducing Events in the Elderly (ASPREE) trial and the ASPREE Cancer Treatment Substudy (ACTS) to describe cancer treatment patterns in older adults. We used a multivariate logistic regression model to identify factors affecting receipt of treatment. Results: Of 1893 eligible Australian and United States (US) participants with incident cancer, 1569 (81%) received some form of cancer treatment. Non-metastatic breast cancers most frequently received treatment (98%), while haematological malignancy received the lowest rates of treatment (60%). Factors associated with not receiving treatment were older age (OR 0.94, 95% CI 0.91–0.96), residence in the US (OR 0.34, 95% CI 0.22–0.54), smoking (OR 0.57, 95% CI 0.40–0.81), and diabetes (OR 0.56, 95% CI 0.39–0.80). After adjustment for treatment patterns in sex-specific cancers, sex did not impact receipt of treatment. Conclusions: This study is one of the first describing cancer treatment patterns and factors affecting receipt of treatment across common cancer types in older adults. We found that most older adults with cancer received some form of cancer treatment, typically surgery or systemic therapy, although this varied by factors such as cancer type, age, sex, and country of residence.

Tumor versus Tumor Cell Targeting in Metal-Based Nanoparticles for Cancer Theranostics

“…are used for diagnosis [14], and tissue tests (through biopsy or cytology) are devoted to both diagnosis and confirmation [15]. As for treatment, there is a plethora of therapeutic approaches to combating cancer, closely dependent on the type and stage of cancer as well as the individual characteristics of the patient [16]. In general terms, the main options are surgical resection of the tumor, chemotherapy, targeted therapy (druggable driver mutations), immunotherapy, and radiotherapy [17,18].…”

The role of NEPA, a combination of netupitant and palonosetron, in the prevention of nausea and vomiting: case report and literature review

“…MEDITSINSKIY SOVET 2023;17 (11):100-107 Supportive therapy ВВЕДЕНИЕ Тошнота и рвота (ТиР), индуцированная химиотерапией, до сих пор остается одним из наиболее часто встречающихся осложнений лечения злокачественных новообразований. Несмотря на активное развитие иммуноонкологической и таргетной терапии, в клинической практике по-прежнему используется большое число эффективных противоопухолевых агентов и их комбинаций, обладаю щих выраженным эметогенным потенциалом [1][2][3]. Проявления этого осложнения во многом определяются субъективными ощущениями и индивидуальными особенностями пациентов, однако в настоящее время общепринятыми являются 4 основных вида ТиР, связанных с химиотерапией [4]: ■ Острая: возникает в течение 0-24 часов с момента проведения химиотерапии.…”